Cedarburg Hauser Pharmaceuticals Leadership Team
R. Anthony Laughrey -- Chief Executive Officer
Charles Boland, MBA -- Executive Vice President
Randy Fortel, MBA CMA -- Vice President of Finance
Joseph Guiles, PhD -- VP of Development & General Manager, InB Hauser Pharmaceutical Services, Inc.
Dan W. Childers, RAC, MT -- Vice President, Corporate Quality and Regulatory Compliance
Richard Pariza, PhD -- Chief Science Officer
Paul Zizelman, MS -- Director of Scientific Operations
John K. Lynch, PhD -- Director of Research and Development
Mark Millar -- Director, Project Management and Resource Coordination
R. Anthony Laughrey
Chief Executive Officer
Tony Laughrey is an accomplished C-Level executive with extensive management, operational, and financial experience. His expertise is in turnaround and revitalization of companies in diverse industries worldwide from bio-pharmaceutical, biotech and life sciences companies, to equipment manufacturing and other low tech industries. He has more than 20 years of success in the value creation process for public and private companies, and has successfully provided turnaround management and leadership to more than 30 portfolio companies.
Cedarburg Pharmaceuticals’ fortunes and profitability have dramatically changed for the better since March 2007. As President and CEO, Mr. Laughrey has redirected the market focus to that of a Contract Development and Manufacturing Organization (CDMO). Cedarburg provides outsourced services to the biotech and pharma industry with chemistry-based offerings from early synthesis and process scale-up through Active Pharmaceutical Ingredient (API) manufacturing in a cGMP environment.
Previously, as organizer, President and CEO of KBI BioPharma, Inc. in Durham NC, an offshoot of Kinetics BioSystems Inc, Mr. Laughrey envisioned and successfully built a revenue-generating biopharmaceutical contract services organization from an initial non-existent cash situation, securing a niche in the $2.5 billion market for biopharmaceutical development outsourcing and opening a pipeline to the emerging global bio-generic markets.
In his earlier career, Mr. Laughrey earned a record of success in providing entrepreneurial solutions and strategic direction to organizations experiencing rapid growth or change. His reputation as a “Rainmaker” has been aptly earned, as Mr. Laughrey has shown innovation and determination in all of his endeavors – forming several high tech companies, securing debt and private equity, leading an international chemical manufacturer through an IPO, and holding numerous Board Director positions leading organizations to achieve competitive success and growth. Mr. Laughrey holds a Bachelor of Science Degree in Chemistry from LeMoyne College. He was Chairman of the Board of Directors for Cell Products, and has served on the boards of several companies, including KBI BioPharma, Inc., Admetric BioChem, Inc., and LCI Management.
Back to Top
Charles Boland
Executive Vice President
Chuck Boland directs the business development, marketing and strategic planning activities at Cedarburg. He has an BS degree from the Illinois Institute of Technology and an MBA from the University of Chicago and more than thirty years experience in sales, marketing and strategic planning at several pharmaceutical and fine chemical companies, including Lonza, Hoffmann-LaRoche and Amoco BioProducts Corporation.
Back to Top
Randy Fortel, MBA CMA
Vice President of Finance
Randy Fortel is an accomplished financial executive with over 17 years of experience helping companies drive profitable growth and improve their overall bottom-line performance while providing valuable leadership in all areas of operational improvement.
Randy has managed the acquisition and divestiture of companies totaling in excess of $100M. He has negotiated credit facilities up to $45M. He has overseen the rapid growth in companies, including a 26% annualized revenue and 39% annualized profit growth over a 6 year period.
Randy is skilled in developing and implementing business drivers, metrics, and financial concepts and he excels in the areas of collaboration, mentoring, and teamwork. He is an expert at establishing and maintaining strong internal controls and ensuring that financial statements are prepared in accordance with GAAP and compliant with SOX.
In his role as Vice President of Finance for Cedarburg Hauser, Randy manages the accounting, finance, audit, risk management, human resource and IT functions. Randy has an MBA and a B.S., Accountancy from California State University at Chico and is a Certified Management Accountant (CMA).
Back to Top
Joseph Guiles, PhD
Vice President of Development & General Manager, InB Hauser Pharmaceutical Services, Inc.
Joseph Guiles, PhD, is a 20 year bioscience veteran in which 18 years were spent in private sector pharmaceutical or biotech startups both in Colorado and New Jersey. His past employers include Sanofi-Aventis, Johnson & Johnson, Sterling-Winthrop and Replidyne. He has directed pharmaceutical R&D, QC, manufacturing and supply chain management operations.
Joe comes to Cedarburg Hauser Pharmaceuticals from MicroRX at CSU Ventures in Fort Collins, Colorado where he was the Executive Director and co-founded two bioscience startup companies. He also co-founded the Colorado Center for Drug Discovery (C2D2), a new initiative to enhance drug discovery capability in Colorado’s public sector.
Joe is an accomplished medicinal chemist having designed three separate agents that have entered human clinical study. Joe has been involved in driving several products to IND and NDA development stage. Joe earned his PhD in chemistry at Colorado State University. His expertise as a organic chemist has been recognized with 25 published research papers, numerous oral papers and 12 issued patents.
Back to Top
Dan Childers
Vice President, Quality Assurance & Regulatory Compliance
Dan Childers directs the Quality Assurance, Quality Control and Regulatory Compliance activities at both the Wisconsin and Colorado sites. He has a B.S. degree in Medical Technology with focused emphasis on microbiology and certification in nuclear medicine. Dan has managed activities for the assurance of product quality in the production of medical products including devices, biologics and pharmaceuticals for over 30 years. During his career he has worked for companies such as Nuclear Medical Laboratories, Organon Teknika, Amgen, BioStar and Hauser Pharmaceutical Services. Dan is Regulatory Affairs Certified through the Regulatory Affairs Professional Society.
Back to Top
Richard Pariza, Ph.D.
Chief Science Officer
Richard Pariza received his Ph.D. degree in Organic Chemistry from Purdue University. He has more than 30 years of leadership on major projects in the pharmaceutical industry. His experience includes positions with Abbott Laboratories, OncQuest, Inc., Protarga, Inc., and Natural Pharmaceuticals. Richard has international recognition as a scientist as well as a scientific manager and leader: Chairman of the prestigious IUPAC Symposium; served on/chaired national ACS committees; frequently invited to chair sessions and lead discussions at international scientific conferences. Former founding editor and now member of the Editorial Board of Organic Process Research & Development, a Research Journal co-sponsored by the American Chemical Society and Royal Society of Chemistry (UK).
Back to Top
Paul Zizelman, MS
Director, Scientific Operations
Paul Zizelman received his BS in Chemistry from Central Michigan University and worked as a graduate research intern at Dow Chemical Co. before starting his Doctoral studies at Indiana University in Bloomington, Indiana. He studied metal mediated organic synthesis under the direction of Professor Jeffrey Mark Stryker. Following graduate school, Paul accepted a position with Aldrich Chemical Company where he became the supervisor of R&D and Glassware production. Capitalizing on ten years in the custom-manufacturing arena, he joined Cedarburg Pharmaceuticals in 1998.
Back to Top
John K. Lynch, PhD
Director of Research and Development
Dr. Lynch oversees all research & development projects for Cedarburg Hauser and our clients to ensure their successful scientific outcomes. John also serves as an expert in the areas of the synthesis of vitamin D analogs, asymmetric synthesis, and synthesis of numerous types of heterocycles and peptide conjugates.
Dr. Lynch received his PhD in organic chemistry from Harvard University in 1992 studying under Professor David Evans where he developed extensive knowledge and expertise in asymmetric synthesis, construction of unnatural amino acids, biaryl bond formation, biaryl ether formation, protection and deprotection strategies, conformational analysis and reaction mechanism.
Dr. Lynch served as a Senior Scientist at Abbott Laboratories where he led medicinal chemistry research projects that focused on metabolic diseases, aging and degenerative diseases, and neuroscience. He also led a variety of process chemistry research projects where he successfully developed or contributed to the efficient synthesis of a nicotinic compound, a platelet aggregating factor antagonist, an HIV protease inhibitor, and an adrenergic compounds.
Dr. Lynch is both accomplished and well respected in the industry. He has been published in peer-reviewed scientific publications 19 times and currently holds 12 patents.
See Dr. Lynch’s full bio and lists of publications and patents.
Back to Top
Mark Millar
Director of Project Management
Mark Millar received his BS in Environmental Science from Royal Roads University in Victoria, British Columbia, Canada. Before assuming his current role as Director of Project Management, Mark previously worked in both Microbiological and Analytical laboratories for API and finished product contract manufacturers.
Mark has developed a very successful approach to project management at Cedarburg Hauser that has consistently delivered a more than 90% on-time, on-budget completion rate for our clients’ projects. He ensures that each of our clients is assigned a single point of contact that is trained to be aware of both the small and big picture details of every project and that each step in the process is recognized and prioritized appropriately.
Mark is based out of our corporate headquarters in Grafton, WI and is responsible for the oversight of the entire Project Management team and all active projects. Mark actively monitors the progress of each project and routinely joins project related discussions to ensure that each customer is completely satisfied with their experience at Cedarburg Hauser Pharmaceuticals. Mark spends 25-50% of his time travelling to either our Denver facility or our clients’ sites to provide in-person support for on-going projects.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
to discuss your current or upcoming drug development or manufacturing project.
Find out more about Cedarburg Hauser’s approach to managing our clients’ projects.
Back to Top
|
